

## THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III AZUR-2 trial is investigating the efficacy and safety of which of the following agents in the perioperative setting for patients with Stage III microsatellite instability-high/mismatch repair-deficient (dMMR) resectable colorectal cancer (CRC)?**

  - Nivolumab
  - Pembrolizumab
  - Dostarlimab**
- 2. Which of the following statements best represents outcomes of the Phase III CALGB/SWOG-80702 trial evaluating the effect of celecoxib versus placebo added to standard adjuvant therapy for patients with Stage III CRC?**

  - No significant improvement in disease-free survival (DFS) for patients with or without detectable circulating tumor DNA (ctDNA)
  - Significant improvement in DFS for patients with detectable ctDNA**
  - Significant improvement in DFS for patients with or without detectable ctDNA
- 3. Which of the following statements best characterizes a clinical research objective of the ongoing Phase II/III NRG-GI008 trial?**

  - To compare DFS rates in the cohort of patients without detectable ctDNA after receiving first-line FOLFOX versus FOLFOX/bevacizumab
  - To compare DFS rates in the cohort of patients with detectable ctDNA after receiving first-line FOLFOX versus FOLFOX/bevacizumab
  - To compare DFS rates in the cohort of patients without detectable ctDNA after disease resection and receiving immediate versus delayed chemotherapy**
- 4. What was the approximate clinical complete response rate in a trial evaluating neoadjuvant dostarlimab for Stage II/III rectal cancer?**

  - 0%
  - 25%
  - 50%
  - 75%
  - 100%**
- 5. The rate of pathologic response observed in the NICHE-2 trial of neoadjuvant nivolumab with ipilimumab for locally advanced dMMR colon cancer is best characterized by which of the following statements?**

  - No pathologic responses were observed in patients
  - A pathologic response was observed in a low proportion of patients
  - A pathologic response was observed in a high proportion of patients**